Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Treat Patients
Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary…
Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary…
Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease…
Genkyotex has announced a new Phase II trial in diabetic kidney disease and patient enrolment…
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United…
Genkyotex, a French biotech with an eye on NASH, has received FDA approval to initiate…
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of…
Which part of our body do European biotechs prefer to target? And how diversified are…
The French biotech Genkyotex has announced Phase II results for GKT137831 in diabetic kidney disease.…